Search
Cadrenal Therapeutics Inc
CVKDAdd to Watchlist
0.985USD
+0.042+4.45%
Close 10-30 16:00（ET）
3.52MMarket Cap
LossP/E TTM
Pre-market 06:42 (ET)1.030USD+0.045+4.57%
Pre-market 06:42 (ET)CVKD Analyst Recommendation Trends
In the current month, CVKD has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CVKD average Analyst price target in the last month is 14.000.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
1
Financial Forecasting
Based on analysts' estimates, CVKD EPS is projected to reach -0.913 in FY2026Q3, following reported EPS of -1.141 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.17
-1.62
-1.42
-0.91
-0.86
Actual
-1.43
-1.04
-1.14
--
--
Surprise
-22.88%
+35.99%
+19.68%
--
--
FAQs
How have Cadrenal Therapeutics IncCVKD's recent earnings per share performed?
The market expectation was USD -1.14, while Cadrenal Therapeutics IncCVKD's earnings per share (EPS) for the previous quarter was USD -1.04. EPS for the next quarter is expected at USD -0.91.
What is the analyst rating for Cadrenal Therapeutics Inc?
Based on the ratings of Cadrenal Therapeutics Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.